New drug combo aims to slow lung scarring and ease cough in IPF patients
NCT ID NCT07583589
First seen May 15, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests whether adding dextromethorphan to the standard drug nidanib helps people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing problems. About 60 adults aged 40 and older with mild to moderate IPF will receive either the combination or a placebo. The main goal is to see if the combination improves lung function (measured by FVC) and reduces cough symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.